181 related articles for article (PubMed ID: 27107614)
1. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
[TBL] [Abstract][Full Text] [Related]
2. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.
Paz De la Rosa G; Monroy-García A; Mora-García Mde L; Peña CG; Hernández-Montes J; Weiss-Steider B; Gómez-Lim MA
Virol J; 2009 Jan; 6():2. PubMed ID: 19126233
[TBL] [Abstract][Full Text] [Related]
3. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
[TBL] [Abstract][Full Text] [Related]
4. Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines.
Zhang T; Chen X; Liao G; Hu M; Xu J; Xu X
J Med Virol; 2020 Dec; 92(12):3750-3758. PubMed ID: 31994744
[TBL] [Abstract][Full Text] [Related]
5. Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.
Hanumantha Rao N; Baji Babu P; Rajendra L; Sriraman R; Pang YY; Schiller JT; Srinivasan VA
Vaccine; 2011 Oct; 29(43):7326-34. PubMed ID: 21803095
[TBL] [Abstract][Full Text] [Related]
6. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
Tumban E; Peabody J; Peabody DS; Chackerian B
PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
[TBL] [Abstract][Full Text] [Related]
7. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.
Fraillery D; Zosso N; Nardelli-Haefliger D
Vaccine; 2009 Apr; 27(17):2326-34. PubMed ID: 19428847
[TBL] [Abstract][Full Text] [Related]
8. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
Thönes N; Müller M
Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
[TBL] [Abstract][Full Text] [Related]
9. Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity.
Schädlich L; Senger T; Kirschning CJ; Müller M; Gissmann L
Vaccine; 2009 Mar; 27(10):1511-22. PubMed ID: 19174177
[TBL] [Abstract][Full Text] [Related]
10. [Prokaryotic expression of HPV 16 L1 gene and identification of its immune activity].
Hao DF; Ma ZH; Wang YP; Rexidan ; Zhang FC
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jul; 21(4):428-31. PubMed ID: 15989783
[TBL] [Abstract][Full Text] [Related]
11. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
[TBL] [Abstract][Full Text] [Related]
12. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
13. Papillomavirus-like particle vaccines.
Schiller JT; Lowy DR
J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
[TBL] [Abstract][Full Text] [Related]
14. Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
García-Piñeres A; Hildesheim A; Dodd L; Kemp TJ; Williams M; Harro C; Lowy DR; Schiller JT; Pinto LA
Clin Vaccine Immunol; 2007 Aug; 14(8):984-9. PubMed ID: 17596432
[TBL] [Abstract][Full Text] [Related]
15. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles.
Xu Y; Zhang H; Xu X
FEMS Immunol Med Microbiol; 2008 Jan; 52(1):99-109. PubMed ID: 17995958
[TBL] [Abstract][Full Text] [Related]
17. HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice.
Berg M; Gambhira R; Siracusa M; Hoiczyk E; Roden R; Ketner G
Vaccine; 2007 Apr; 25(17):3501-10. PubMed ID: 16914239
[TBL] [Abstract][Full Text] [Related]
18. Expression, purification, and antibody binding activity of human papillomavirus 16 L1 protein fused to maltose binding protein.
Cho HJ; Hahm MS; Kim MK; Han IK; Jung WW; Choi HG; Kim JA; Oh YK
Protein Pept Lett; 2007; 14(5):417-24. PubMed ID: 17584165
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
20. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
